Meeting
2021 ASCO Annual Meeting
Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.
Authors
Shukui Qin
Chinese People's Liberation Army Cancer Center of Nanjing Bayi Hospital, Nanjing, China
Shukui Qin , Jin Li , Haijun Zhong , Chuan Jin , Lili Chen , Xianglin Yuan , Qingxia Fan , Kehe Chen , Peiguo Cao , Jianjun Xiao , Da Jiang , Tao Zhang , Hongyu Zhang , Xicheng Wang , Wei Wang , Qingyu Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Monotherapy
Clinical Trial Registration Number
NCT03941574
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2566)
DOI
10.1200/JCO.2021.39.15_suppl.2566
Abstract #
2566
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of camrelizumab combined with apatinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial.
First Author: Lin-Quan Tang
Poster
2021 ASCO Annual Meeting
A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.
First Author: Jian Li
Poster
2020 ASCO Virtual Scientific Program
A phase II trial of PD-1 inhibition with INCMGA00012 in patients with previously treated unresectable or metastatic adenosquamous pancreatic cancer.
First Author: Christopher Jakubowski